Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314573 | 0.93 | ALDH1A1 (0.53) | HRH2HRH1KMT2AHRH3ALDH1A1 | |
| SCHEMBL6285686 | 0.90 | HRH2 (0.60) | HRH2HRH1KMT2AHRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL16107158 | 0.89 | HRH3 (0.62) | HRH2HRH1HRH3ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL16107182 | 0.88 | HRH3 (0.60) | HRH2HRH1HRH3ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL16694955 | 0.88 | HRH3 (0.60) | HRH2HRH1HRH3ALDH1A1KDM4E | |
| SCHEMBL23061496 | 0.87 | HRH2 (0.51) | HRH2HRH1KMT2AHRH3ALDH1A1 | |
| SCHEMBL521113 | 0.83 | HRH3 (0.71) | HRH2HRH1KMT2AHRH3ALDH1A1 | |
| SCHEMBL763025 | 0.82 | HTR2A (0.57) | KMT2AALDH1A1SMN1; SMN2HTR2AMAPT | |
| SCHEMBL16088361 | 0.81 | KDM4E (0.67) | HRH2HRH1KMT2AHRH3ALDH1A1 | |
| SCHEMBL1144551 | 0.81 | MGLL (0.62) | KMT2AALDH1A1SMN1; SMN2TDP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030123-B2 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| EP-1289952-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092224-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | IDO1, IDO2, VEGFA | HRH2 73/4885HRH1 160/4885KMT2A 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.